Fundraising Fox
Sharptx
1 known investors
Find your way into Sharptx
Sign up to see every warm intro you have to Sharptx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sharptx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sharp Therapeutics develops a small molecule drug platform designed to treat genetic diseases more affordably and quickly than current biologics and gene therapies. The company targets patients and payors seeking faster, scalable alternatives to existing genetic disease treatments.
Founders & leadership
SS
Scott SneddonCEOScott Sneddon holds training in chemistry and biology with computational expertise and has led drug discovery teams across large pharmaceutical and biotech companies, with particular experience in assay development and high-throughput screening. He holds a law degree and has managed business development activities including licensing and acquisition negotiations.
Investors · 1
Frequently asked questions
- What does Sharptx do?
- Sharp Therapeutics develops a small molecule drug platform designed to treat genetic diseases more affordably and quickly than current biologics and gene therapies. The company targets patients and payors seeking faster, scalable alternatives to existing genetic disease treatments.
- Who are Sharptx's investors?
- Sharptx's investors include Newlin Investment Company LLC.